S&P 500

Biogen (BIIB) — 10-Year DCF Projection Model

Free stock research tool. Build a 10-year revenue, earnings (EPS), and free cash flow forecast for Biogen (BIIB) stock, a company in the Health Care (Biotechnology) sector. Pulls audited SEC EDGAR XBRL financials, triangulates Wall Street analyst consensus across Yahoo Finance, NASDAQ, and StockAnalysis, and overlays AI-clustered news + social event probabilities directly onto projected EPS. For equity research — not personal budgeting or accounting.

Build BIIB projection model →Browse all stocks

Biogen at a glance

Ticker
BIIB
Company
Biogen
Sector
Health Care
Sub-industry
Biotechnology
Headquarters
Cambridge, Massachusetts
Founded
1978
Added to S&P 500
2003-11-13
Index membership
S&P 500

What you'll see in your BIIB model

  • 10 years of audited historical financials for Biogen, sourced directly from the SEC's EDGAR XBRL filings (10-K and 10-Q).
  • Triangulated Wall Street consensus for BIIB's forward revenue, EBITDA, and EPS across Yahoo Finance, NASDAQ, and StockAnalysis with cross-source dispersion (σ).
  • AI Event Factors: top-10 news/social themes for BIIB with probability sliders and live EPS impact.
  • Sensitivity tables and Excel export for every assumption.

About Biogen

Biogen (NYSE/NASDAQ: BIIB) was founded in 1978 and is headquartered in Cambridge, Massachusetts. The company operates in the Health Care sector (Biotechnology sub-industry) and is a constituent of the S&P 500. Our projection model builds a clean discounted-cash-flow view of Biogen in roughly five seconds and lets you adjust every assumption to test your own thesis.